Atlas FDA

Alinity m HBV

FDA premarket approval P200013/S015 · decided 2023-07-18

Approval details

PMA number
P200013
Supplement
S015
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
Alinity m HBV
Generic name
Hepatitis Viral B DNA Detection
Applicant
Abbott Molecular, Inc.
Date received
2023-05-01
Decision date
2023-07-18
Days to decision
78 days
Decision code
APPR
Product code
MKT
Advisory committee
Microbiology
Expedited review
No
Location
Des Plaines, IL
Statement
Approval for a change of the Alinity m HBV Assay to implement a new application specification file containing an improved PCR reagent assembly process that mitigates the potential for overflow at the Alinity m Amplification (AMP) Tray, thus minimizing the potential risk for carryover. The Alinity m HBV Kit package insert is also being updated to reflect the carryover rate using the new application specification file.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Alinity m HCV (K252102)Abbott Molecular, Inc.2025-09-25
Alinity m EBV (09N43-095) (K243489)Abbott Molecular, Inc.2025-07-28
Alinity m CMV (K243485)Abbott Molecular, Inc.2025-07-01
Alinity m BKV (K241921)Abbott Molecular, Inc.2025-03-24
Alinity m Resp-4-Plex (K241573)Abbott Molecular, Inc.2025-02-14
Alinity m HSV 1 & 2 / VZV (K233349)Abbott Molecular, Inc.2024-05-03
Alinity m STI Assay (K222379)Abbott Molecular, Inc.2023-03-03
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075) (K212778)Abbott Molecular, Inc.2022-07-15